stockrow
Saturday 7 November 2026
Export DMAA’s income statement to Excel — free account
Drugs Made In America Acquisition Corp.
DMAA Financial Shell Companies
10.89
0.00
0.00%
Follow DMAA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Net income | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | — | — | |||||
| Earnings | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Book value | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Shares, m | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | — | — | |||||
| ROIC | — | — | — | — | — | — | — | — | — | — | — | ||||||
| ROE | — | — | — | — | — | — | — | — | — | — | — | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | — | ||||||
Negative figures in brackets.
estimates
Drugs Made In America Acquisition Corp. vs peers in Shell Companies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SOUL Soulpower Acquisition Corporation | $275.3M | — | — | — | — | — | — | — | Compare |
| MUZE Muzero Acquisition Corp | $273.3M | — | — | — | — | — | — | — | Compare |
| DNMX Dynamix Corporation III | $271.3M | — | — | — | — | — | — | 0.00% | Compare |
| CATL Catalyst Acquisition Corp. | $267.1M | — | — | — | — | — | — | — | Compare |
| DMAA Drugs Made In America Acquisition Corp. | $264.4M | — | — | — | — | — | — | — | |
| OACC Oaktree Acquisition Corp. III Life Sciences | $262.7M | — | — | — | — | — | — | — | Compare |
| TRGS TRG Latin America Acquisitions Corp. | $259.4M | — | — | — | — | — | — | — | Compare |
| RAC Rithm Acquisition Corp. | $255.6M | — | — | — | — | — | — | — | Compare |
| PNAQ Pinnacle Acquisition Corporation | $254.4M | — | — | — | — | — | — | — | Compare |
| Median of peers | $264.9M | — | — | — | — | — | — | — |
Pay and ownership Proxy statement filed 14 April 2026
Ownership
Directors and executive officers, together
less than 1%
Drugs Made In America Acquisition LLC
12.50%
Lynn Stockwell
12.50%
Karpus Management, Inc.
8.20%
First Trust Capital Management L.P.
6.20%
First Trust Capital Solutions L.P.
6.20%
FTCS Sub GP LLC
6.20%
Polar Asset Management Partners Inc.
5.70%
Glazer Capital, LLC
5.40%
Paul J. Glazer
5.40%
First Trust Merger Arbitrage Fund
5.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement